Characteristics of Patients Treated With Continuous Infusion Meropenem According to Target Nonattainment (<8 mg/L) and Potentially Toxic Drug Concentrations (>44.5 mg/L) at First TDMa
| . | Meropenem Concentration at First TDM . | |||
|---|---|---|---|---|
| . | <8 mg/L . | 8–44.5 mg/L . | >44.5 mg/L . | P Value . |
| Characteristic . | n = 8 . | n = 160 . | n = 18 . | . |
| Sex (female) | 3 (37.5%) | 40 (25.0%) | 7 (38.9%) | .36 |
| Age (years) | 59 (48–64) | 66 (55–74) | 70 (62–75) | .068 |
| Weight | 88 (76–111) | 80 (68–90) | 71 (52–85) | .092 |
| Height | 175 (168–180) | 172 (168–180) | 165 (157–176) | .19 |
| BMI (kg/m2) | 27 (25–37) | 26 (23–30) | 24 (23–27) | .19 |
| ICU Admission Type | .57 | |||
| Medical | 3 (37.5%) | 91 (56.9%) | 9 (50.0%) | |
| Surgical | 4 (50.0%) | 55 (34.4%) | 5 (27.8%) | |
| Missing | 1 (12.5%) | 14 (8.8%) | 4 (22.2%) | |
| Time on ICU before measurement of drug concentration (days) | 3 (2–5) | 4 (2–10) | 3 (1–9) | .50 |
| Charlson comorbidity score | 0 (0–5) | 2 (1–5) | 3 (2–5) | .16 |
| Mechanical ventilation | 4 (50.0%) | 94 (58.8%) | 11 (61.1%) | .86 |
| ECMO | 0 (0.0%) | 11 (6.9%) | 1 (5.6%) | .73 |
| CRRT | 0 (0.0%) | 33 (20.6%) | 3 (16.7%) | .34 |
| Vasopressor therapy | 1 (12.5%) | 38 (23.8%) | 9 (50.0%) | .037 |
| Time on meropenem until concentration measurement (hours) | 27 (16–39) | 23 (15–42) | 20 (14–37) | .60 |
| Creatinine (µmol/L) | 66 (49–90) | 104 (66–178) | 185 (89–242) | .020 |
| eGFR (mL/min/1.73 m2) | 99 (79–113) | 64 (32–92) | 31 (22–69) | .004 |
| C-reactive protein (mg/L) | 139 (75–265) | 193 (102–298) | 187 (140–353) | .42 |
| Hemoglobin (g/L) | 100 (87–113) | 87 (81–98) | 85 (81–100) | .31 |
| Leucocyte count (×109/L) | 9.5 (6.4–14.9) | 12.6 (8.8–18.5) | 10.9 (7.8–14.5) | .27 |
| Albumin (g/L) | 19 (17–21) | 20 (18–23) | 21 (19–22) | .66 |
| Total protein (g/L) | 59 (58–66) | 55 (50–61) | 53 (48–60) | .041 |
| Total Daily Dosage (g/day) | .53 | |||
| 1 | 0 (0.0%) | 9 (5.6%) | 0 (0.0%) | |
| 2 | 1 (12.5%) | 25 (15.6%) | 2 (11.1%) | |
| 3 | 5 (62.5%) | 77 (48.1%) | 7 (38.9%) | |
| 4 | 0 (0.0%) | 4 (2.5%) | 2 (11.1%) | |
| 6 | 2 (25.0%) | 45 (28.1%) | 7 (38.9%) | |
| . | Meropenem Concentration at First TDM . | |||
|---|---|---|---|---|
| . | <8 mg/L . | 8–44.5 mg/L . | >44.5 mg/L . | P Value . |
| Characteristic . | n = 8 . | n = 160 . | n = 18 . | . |
| Sex (female) | 3 (37.5%) | 40 (25.0%) | 7 (38.9%) | .36 |
| Age (years) | 59 (48–64) | 66 (55–74) | 70 (62–75) | .068 |
| Weight | 88 (76–111) | 80 (68–90) | 71 (52–85) | .092 |
| Height | 175 (168–180) | 172 (168–180) | 165 (157–176) | .19 |
| BMI (kg/m2) | 27 (25–37) | 26 (23–30) | 24 (23–27) | .19 |
| ICU Admission Type | .57 | |||
| Medical | 3 (37.5%) | 91 (56.9%) | 9 (50.0%) | |
| Surgical | 4 (50.0%) | 55 (34.4%) | 5 (27.8%) | |
| Missing | 1 (12.5%) | 14 (8.8%) | 4 (22.2%) | |
| Time on ICU before measurement of drug concentration (days) | 3 (2–5) | 4 (2–10) | 3 (1–9) | .50 |
| Charlson comorbidity score | 0 (0–5) | 2 (1–5) | 3 (2–5) | .16 |
| Mechanical ventilation | 4 (50.0%) | 94 (58.8%) | 11 (61.1%) | .86 |
| ECMO | 0 (0.0%) | 11 (6.9%) | 1 (5.6%) | .73 |
| CRRT | 0 (0.0%) | 33 (20.6%) | 3 (16.7%) | .34 |
| Vasopressor therapy | 1 (12.5%) | 38 (23.8%) | 9 (50.0%) | .037 |
| Time on meropenem until concentration measurement (hours) | 27 (16–39) | 23 (15–42) | 20 (14–37) | .60 |
| Creatinine (µmol/L) | 66 (49–90) | 104 (66–178) | 185 (89–242) | .020 |
| eGFR (mL/min/1.73 m2) | 99 (79–113) | 64 (32–92) | 31 (22–69) | .004 |
| C-reactive protein (mg/L) | 139 (75–265) | 193 (102–298) | 187 (140–353) | .42 |
| Hemoglobin (g/L) | 100 (87–113) | 87 (81–98) | 85 (81–100) | .31 |
| Leucocyte count (×109/L) | 9.5 (6.4–14.9) | 12.6 (8.8–18.5) | 10.9 (7.8–14.5) | .27 |
| Albumin (g/L) | 19 (17–21) | 20 (18–23) | 21 (19–22) | .66 |
| Total protein (g/L) | 59 (58–66) | 55 (50–61) | 53 (48–60) | .041 |
| Total Daily Dosage (g/day) | .53 | |||
| 1 | 0 (0.0%) | 9 (5.6%) | 0 (0.0%) | |
| 2 | 1 (12.5%) | 25 (15.6%) | 2 (11.1%) | |
| 3 | 5 (62.5%) | 77 (48.1%) | 7 (38.9%) | |
| 4 | 0 (0.0%) | 4 (2.5%) | 2 (11.1%) | |
| 6 | 2 (25.0%) | 45 (28.1%) | 7 (38.9%) | |
Abbreviations: BMI, body mass index; CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation; eGFR, estimated glomerular filtration rate; ICU, intensive care unit; TDM, therapeutic drug monitoring.
Data are presented as count (percentages) or median (interquartile range).
Characteristics of Patients Treated With Continuous Infusion Meropenem According to Target Nonattainment (<8 mg/L) and Potentially Toxic Drug Concentrations (>44.5 mg/L) at First TDMa
| . | Meropenem Concentration at First TDM . | |||
|---|---|---|---|---|
| . | <8 mg/L . | 8–44.5 mg/L . | >44.5 mg/L . | P Value . |
| Characteristic . | n = 8 . | n = 160 . | n = 18 . | . |
| Sex (female) | 3 (37.5%) | 40 (25.0%) | 7 (38.9%) | .36 |
| Age (years) | 59 (48–64) | 66 (55–74) | 70 (62–75) | .068 |
| Weight | 88 (76–111) | 80 (68–90) | 71 (52–85) | .092 |
| Height | 175 (168–180) | 172 (168–180) | 165 (157–176) | .19 |
| BMI (kg/m2) | 27 (25–37) | 26 (23–30) | 24 (23–27) | .19 |
| ICU Admission Type | .57 | |||
| Medical | 3 (37.5%) | 91 (56.9%) | 9 (50.0%) | |
| Surgical | 4 (50.0%) | 55 (34.4%) | 5 (27.8%) | |
| Missing | 1 (12.5%) | 14 (8.8%) | 4 (22.2%) | |
| Time on ICU before measurement of drug concentration (days) | 3 (2–5) | 4 (2–10) | 3 (1–9) | .50 |
| Charlson comorbidity score | 0 (0–5) | 2 (1–5) | 3 (2–5) | .16 |
| Mechanical ventilation | 4 (50.0%) | 94 (58.8%) | 11 (61.1%) | .86 |
| ECMO | 0 (0.0%) | 11 (6.9%) | 1 (5.6%) | .73 |
| CRRT | 0 (0.0%) | 33 (20.6%) | 3 (16.7%) | .34 |
| Vasopressor therapy | 1 (12.5%) | 38 (23.8%) | 9 (50.0%) | .037 |
| Time on meropenem until concentration measurement (hours) | 27 (16–39) | 23 (15–42) | 20 (14–37) | .60 |
| Creatinine (µmol/L) | 66 (49–90) | 104 (66–178) | 185 (89–242) | .020 |
| eGFR (mL/min/1.73 m2) | 99 (79–113) | 64 (32–92) | 31 (22–69) | .004 |
| C-reactive protein (mg/L) | 139 (75–265) | 193 (102–298) | 187 (140–353) | .42 |
| Hemoglobin (g/L) | 100 (87–113) | 87 (81–98) | 85 (81–100) | .31 |
| Leucocyte count (×109/L) | 9.5 (6.4–14.9) | 12.6 (8.8–18.5) | 10.9 (7.8–14.5) | .27 |
| Albumin (g/L) | 19 (17–21) | 20 (18–23) | 21 (19–22) | .66 |
| Total protein (g/L) | 59 (58–66) | 55 (50–61) | 53 (48–60) | .041 |
| Total Daily Dosage (g/day) | .53 | |||
| 1 | 0 (0.0%) | 9 (5.6%) | 0 (0.0%) | |
| 2 | 1 (12.5%) | 25 (15.6%) | 2 (11.1%) | |
| 3 | 5 (62.5%) | 77 (48.1%) | 7 (38.9%) | |
| 4 | 0 (0.0%) | 4 (2.5%) | 2 (11.1%) | |
| 6 | 2 (25.0%) | 45 (28.1%) | 7 (38.9%) | |
| . | Meropenem Concentration at First TDM . | |||
|---|---|---|---|---|
| . | <8 mg/L . | 8–44.5 mg/L . | >44.5 mg/L . | P Value . |
| Characteristic . | n = 8 . | n = 160 . | n = 18 . | . |
| Sex (female) | 3 (37.5%) | 40 (25.0%) | 7 (38.9%) | .36 |
| Age (years) | 59 (48–64) | 66 (55–74) | 70 (62–75) | .068 |
| Weight | 88 (76–111) | 80 (68–90) | 71 (52–85) | .092 |
| Height | 175 (168–180) | 172 (168–180) | 165 (157–176) | .19 |
| BMI (kg/m2) | 27 (25–37) | 26 (23–30) | 24 (23–27) | .19 |
| ICU Admission Type | .57 | |||
| Medical | 3 (37.5%) | 91 (56.9%) | 9 (50.0%) | |
| Surgical | 4 (50.0%) | 55 (34.4%) | 5 (27.8%) | |
| Missing | 1 (12.5%) | 14 (8.8%) | 4 (22.2%) | |
| Time on ICU before measurement of drug concentration (days) | 3 (2–5) | 4 (2–10) | 3 (1–9) | .50 |
| Charlson comorbidity score | 0 (0–5) | 2 (1–5) | 3 (2–5) | .16 |
| Mechanical ventilation | 4 (50.0%) | 94 (58.8%) | 11 (61.1%) | .86 |
| ECMO | 0 (0.0%) | 11 (6.9%) | 1 (5.6%) | .73 |
| CRRT | 0 (0.0%) | 33 (20.6%) | 3 (16.7%) | .34 |
| Vasopressor therapy | 1 (12.5%) | 38 (23.8%) | 9 (50.0%) | .037 |
| Time on meropenem until concentration measurement (hours) | 27 (16–39) | 23 (15–42) | 20 (14–37) | .60 |
| Creatinine (µmol/L) | 66 (49–90) | 104 (66–178) | 185 (89–242) | .020 |
| eGFR (mL/min/1.73 m2) | 99 (79–113) | 64 (32–92) | 31 (22–69) | .004 |
| C-reactive protein (mg/L) | 139 (75–265) | 193 (102–298) | 187 (140–353) | .42 |
| Hemoglobin (g/L) | 100 (87–113) | 87 (81–98) | 85 (81–100) | .31 |
| Leucocyte count (×109/L) | 9.5 (6.4–14.9) | 12.6 (8.8–18.5) | 10.9 (7.8–14.5) | .27 |
| Albumin (g/L) | 19 (17–21) | 20 (18–23) | 21 (19–22) | .66 |
| Total protein (g/L) | 59 (58–66) | 55 (50–61) | 53 (48–60) | .041 |
| Total Daily Dosage (g/day) | .53 | |||
| 1 | 0 (0.0%) | 9 (5.6%) | 0 (0.0%) | |
| 2 | 1 (12.5%) | 25 (15.6%) | 2 (11.1%) | |
| 3 | 5 (62.5%) | 77 (48.1%) | 7 (38.9%) | |
| 4 | 0 (0.0%) | 4 (2.5%) | 2 (11.1%) | |
| 6 | 2 (25.0%) | 45 (28.1%) | 7 (38.9%) | |
Abbreviations: BMI, body mass index; CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation; eGFR, estimated glomerular filtration rate; ICU, intensive care unit; TDM, therapeutic drug monitoring.
Data are presented as count (percentages) or median (interquartile range).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
